News
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the Medicines and Healthcare products Regulatory Agency ...
KalVista Pharmaceuticals has received marketing authorization in the U.K. for Ekterly, its treatment for hereditary angioedema attacks.
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided an operational update and released financial results for the fiscal year ended April 30, 2025.
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company whose mission is to develop and deliver life-changing oral medicines for people affected by rare diseases with significant unmet ...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Ekterly (sebetralstat) 0for the ...
The US Food and Drug Administration (FDA) last week authorized KalVista Pharmaceutical’s Ekterly for the treatment of acute ...
Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...
Received FDA approval of EKTERLY® (sebetralstat)-the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway - - Six additional global regulatory submissions under ...
9h
Everyday Health on MSNHereditary Angioedema (HAE) Attacks Can Now Be Treated With a PillHAE attacks can now be treated with a pill, Ekterly (sebetralstat), instead by injection or infusion. That could translate to faster symptom relief.
Detailed price information for Elanco Animal Health Inc (ELAN-N) from The Globe and Mail including charting and trades.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 15 July 2025, approved sebetralstat (Ekterly) for ...
Review the current KalVista Pharmaceuticals Inc (KALV:XNAS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if KALV is the best investment for you.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results